Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) EBIT (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed EBIT for 9 consecutive years, with $99170.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 58.42% year-over-year to $99170.0, compared with a TTM value of $1.3 million through Oct 2025, up 391.7%, and an annual FY2025 reading of $1.2 million, up 487.62% over the prior year.
  • EBIT was $99170.0 for Q4 2025 at VitaNova Life Sciences, up from -$32440.0 in the prior quarter.
  • Across five years, EBIT topped out at $1.1 million in Q2 2025 and bottomed at -$45414.0 in Q3 2024.
  • Average EBIT over 5 years is $71649.2, with a median of -$481.0 recorded in 2021.
  • The sharpest move saw EBIT plummeted 1236.22% in 2023, then soared 5406.34% in 2024.
  • Year by year, EBIT stood at -$29991.0 in 2021, then surged by 108.67% to $2601.0 in 2022, then tumbled by 436.6% to -$8755.0 in 2023, then surged by 815.02% to $62600.0 in 2024, then soared by 58.42% to $99170.0 in 2025.
  • Business Quant data shows EBIT for YJGJ at $99170.0 in Q4 2025, -$32440.0 in Q3 2025, and $1.1 million in Q2 2025.